2026 Q3 Portfolio Activity
In 2026 Q3, Frazier Life Sciences Management, L.P. maintained a portfolio of 47 distinct positions. The most significant new addition was ATTOVIA THERAPEUTICS INC, now representing 3.00% of the total fund value. They heavily accumulated shares in MANNKIND CORP, increasing the position by 138.7%. Conversely, Frazier Life Sciences Management, L.P. completely exited their position in BRIDGEBIO PHARMA INC.
Position History
hover any row below to update
Loading…
Frazier Life Sciences Management, L.P.
Seattle, WA
Life Sciences Venture Capital / Growth Equity
AUM $4,031M
Total Positions
47
Quarter
2026 Q3
Top Holding
MIRM (16.3%)
Top 10 Concentration
70.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-47 of 47
Frazier Life Sciences Management, L.P. Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 16.29% | 19.58% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
7,679,684 | $656,459,388 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 11.46% | 13.35% |
#2
Prev: #2
|
6.0 |
—
|
900,000 | 5.0% |
P
S
|
18,988,902 | $461,810,097 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ERAS
ERASCA INC
|
Healthcare | 10.72% | 9.96% |
#3
Prev: #3
|
7.0 |
—
|
4,500,000 | 18.0% |
P
S
|
29,475,188 | $432,106,256 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 9.67% | 8.00% |
#4
Prev: #4
|
5.4 |
—
|
no change | no change |
P
S
|
6,652,013 | $389,941,002 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ARQT
ARCUTIS BIOTHER...
|
Healthcare | 6.48% | 5.64% |
#5
Prev: #5
|
4.1 |
—
|
no change | no change |
P
S
|
9,874,511 | $260,983,326 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 3.56% | 3.27% |
#6
2
Prev: #8
|
1.9 |
—
|
250,000 | 5.0% |
P
S
|
5,282,915 | $143,589,630 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 3.39% | 4.04% |
#7
1
Prev: #6
|
1.9 |
—
|
-400,300 | -4.0% |
P
S
|
9,539,147 | $136,600,585 | 2022 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 3.23% | 3.90% |
#8
1
Prev: #7
|
1.8 |
—
|
-89,988 | -18.7% |
P
S
|
391,319 | $130,137,047 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PVLA
PALVELLA THERAP...
|
Healthcare | 3.02% | 2.94% |
#9
1
Prev: #10
|
2.2 |
—
|
no change | no change |
P
S
|
882,400 | $121,709,432 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
ATTOVIA THERAPE...
|
|
Unknown | 3.00% | — |
#10
Prev: #—
|
4.7 |
—
|
7,046,271 | — |
NEW
|
7,046,271 | $120,773,085 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
BRVE
BRAVEHEART BIO ...
|
Healthcare | 2.64% | — |
#11
Prev: #—
|
4.6 |
—
|
5,267,321 | — |
NEW
|
5,267,321 | $106,399,884 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 2.26% | 2.95% |
#12
3
Prev: #9
|
1.9 |
—
|
no change | no change |
P
S
|
12,466,489 | $91,005,370 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PBLS
PARABILIS MEDIC...
|
Healthcare | 1.87% | 1.14% |
#13
4
Prev: #17
|
3.2 |
—
|
409,945 | 21.3% |
P
S
|
2,330,750 | $75,259,918 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 1.54% | 1.53% |
#14
Prev: #14
|
3.1 |
—
|
700,000 | 22.2% |
P
S
|
3,853,082 | $62,073,151 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACHV
ACHIEVE LIFE SC...
|
Healthcare | 1.53% | 1.08% |
#15
4
Prev: #19
|
1.6 |
—
|
no change | no change |
P
S
|
7,614,836 | $61,604,023 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MNKD
MANNKIND CORP
|
Healthcare | 1.52% | 0.61% |
#16
11
Prev: #27
|
3.6 |
—
|
9,155,491 | 138.7% |
P
S
|
15,755,491 | $61,446,415 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 1.52% | 2.16% |
#17
5
Prev: #12
|
0.6 |
—
|
-420,000 | -31.0% |
P
S
|
934,852 | $61,195,412 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 1.40% | 1.00% |
#18
4
Prev: #22
|
1.1 |
—
|
-8,306 | -1.1% |
P
S
|
720,338 | $56,625,770 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 1.30% | 1.02% |
#19
1
Prev: #20
|
2.5 |
—
|
200,000 | 7.9% |
P
S
|
2,743,939 | $52,354,356 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 1.27% | 1.31% |
#20
5
Prev: #15
|
1.5 |
—
|
no change | no change |
P
S
|
225,155 | $51,297,064 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ZLAB
ZAI LAB LTD
|
Healthcare | 1.24% | 0.79% |
#21
5
Prev: #26
|
1.5 |
—
|
no change | no change |
P
S
|
1,902,320 | $50,107,109 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 1.14% | 0.57% |
#22
7
Prev: #29
|
3.5 |
—
|
3,804,142 | 77.2% |
P
S
|
8,729,516 | $45,917,254 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AURA
AURA BIOSCIENCE...
|
Healthcare | 1.11% | 1.10% |
#23
5
Prev: #18
|
1.4 |
—
|
no change | no change |
P
S
|
7,100,000 | $44,588,000 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALLO
ALLOGENE THERAP...
|
Healthcare | 0.89% | 1.02% |
#24
3
Prev: #21
|
1.4 |
—
|
no change | no change |
P
S
|
22,446,668 | $35,914,669 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 0.83% | 0.87% |
#25
2
Prev: #23
|
1.3 |
—
|
no change | no change |
P
S
|
4,009,240 | $33,396,969 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.72% | — |
#26
Prev: #—
|
3.8 |
—
|
900,080 | — |
NEW
|
900,080 | $29,171,593 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 0.72% | 0.79% |
#27
2
Prev: #25
|
1.3 |
—
|
no change | no change |
P
S
|
1,438,198 | $28,979,690 | 2022 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
STTK
SHATTUCK LABS I...
|
Healthcare | 0.63% | 0.57% |
#28
2
Prev: #30
|
1.3 |
—
|
no change | no change |
P
S
|
3,750,000 | $25,575,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 0.62% | 0.34% |
#29
7
Prev: #36
|
3.2 |
—
|
344,970 | 71.2% |
P
S
|
829,752 | $25,133,188 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DSGN
DESIGN THERAPEU...
|
Healthcare | 0.56% | 0.57% |
#30
2
Prev: #28
|
1.2 |
—
|
no change | no change |
P
S
|
1,809,854 | $22,749,865 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EOLS
EVOLUS INC
|
Healthcare | 0.52% | 0.40% |
#31
4
Prev: #35
|
1.2 |
—
|
no change | no change |
P
S
|
2,630,665 | $21,045,320 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SRPT
SAREPTA THERAPE...
|
Healthcare | 0.48% | — |
#32
Prev: #—
|
3.7 |
—
|
1,069,959 | — |
NEW
|
1,069,959 | $19,494,653 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 0.45% | 0.41% |
#33
1
Prev: #34
|
1.2 |
—
|
no change | no change |
P
S
|
1,015,693 | $18,333,259 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.40% | 0.49% |
#34
1
Prev: #33
|
1.2 |
—
|
no change | no change |
P
S
|
4,824,725 | $16,307,571 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VALN
VALNEVA SE
|
Healthcare | 0.35% | 0.26% |
#35
2
Prev: #37
|
1.1 |
—
|
no change | no change |
P
S
|
2,291,666 | $14,173,954 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KLRA
KAILERA THERAPE...
|
Healthcare | 0.34% | 0.53% |
#36
5
Prev: #31
|
2.1 |
—
|
100,000 | 9.1% |
P
S
|
1,200,000 | $13,704,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GLUE
MONTE ROSA THER...
|
Healthcare | 0.30% | 0.53% |
#37
5
Prev: #32
|
1.1 |
—
|
no change | no change |
P
S
|
1,000,000 | $11,930,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ORIC
ORIC PHARMACEUT...
|
Healthcare | 0.25% | — |
#38
Prev: #—
|
3.6 |
—
|
751,672 | — |
NEW
|
751,672 | $10,125,022 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AUTL
AUTOLUS THERAPE...
|
Healthcare | 0.21% | 0.15% |
#39
Prev: #39
|
1.1 |
—
|
no change | no change |
P
S
|
4,447,910 | $8,628,945 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NAMSW
NEWAMSTERDAM PH...
|
Unknown | 0.16% | 0.23% |
#40
2
Prev: #38
|
1.1 |
—
|
no change | no change |
P
S
|
500,333 | $6,329,212 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SVRA
SAVARA INC
|
Healthcare | 0.14% | 1.30% |
#41
25
Prev: #16
|
0.1 |
—
|
-8,607,100 | -88.5% |
P
S
|
1,113,752 | $5,746,960 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XLO
XILIO THERAPEUT...
|
Healthcare | 0.09% | 0.09% |
#42
2
Prev: #40
|
1.0 |
—
|
no change | no change |
P
S
|
422,505 | $3,823,670 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
TCGX ACQUISITIO...
|
|
Unknown | 0.09% | — |
#43
Prev: #—
|
3.5 |
—
|
300,000 | — |
NEW
|
300,000 | $3,753,000 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
IBIO
IBIO INC
|
Healthcare | 0.06% | 0.07% |
#44
3
Prev: #41
|
1.0 |
—
|
no change | no change |
P
S
|
1,953,467 | $2,305,091 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 0.00% | 0.80% |
Sold All 😨
(Was: #24) |
0.0 |
—
|
-700,647 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 0.00% | 2.15% |
Sold All 😨
(Was: #13) |
0.0 |
—
|
-1,159,879 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 0.00% | 2.51% |
Sold All 😨
(Was: #11) |
0.0 |
—
|
-1,548,139 | -100.0% |
CLOSED
|
— | $— | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-47 of 47 holdings